CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology: A Detailed Invasive Hemodynamic and Echocardiographic Analysis The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial Impact of Intravascular Ultrasound-Guided Percutaneous Coronary Intervention on Long-Term Clinical Outcomes in Patients Undergoing Complex Procedures 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel) Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial IVUS in bifurcation stenting: what have we learned? Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions: Endorsed by the Chinese Society of Cardiology Novel predictor of target vessel revascularization after coronary stent implantation: Intraluminal intensity of blood speckle on intravascular ultrasound The Year in Cardiovascular Medicine 2020: Imaging: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of imaging are Fausto Pinto, José Luis Zamorano and Chiara Bucciarelli-Ducci. Judy Ozkan speaks with them Optical coherence tomography and intravascular ultrasound assessment of the anatomic size and wall thickness of a muscle bridge segment

Expert Opinion

JOURNAL:ACC Article Link

Randomized Comparison of Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis - RECOVERY

Dharam J. Kumbhani

Pre-reading

CONTRIBUTION TO LITERATURE - The RECOVERY trial showed that early surgery among patients with asymptomatic but very severe aortic stenosis results in improved survival out to 8 years compared with watchful waiting.


DESCRIPTION - The goal of the trial was to assess the safety and benefit of surgery vs. watchful waiting among patients with asymptomatic very severe aortic stenosis.


STUDY DESIGN

Eligible patients with very severe asymptomatic aortic stenosis were randomized in a 1:1 open-label fashion to either early surgical aortic valve replacement (AVR) (n = 73) or watchful waiting (n = 72).

- Total screened: 273

- Total number of enrollees: 145

- Duration of follow-up: 6.2 years

- Mean patient age: 64.2 years

- Percentage female: 51%


INCLUSION CRITERIA:

- Age 20-80 years

- Very severe aortic stenosis (aortic valve area [AVA] 0.75 cm2, peak velocity 4.5 m/sec, or mean gradient 50 mm Hg)

- Lack of symptoms


EXCLUSION CRITERIA:

- Exertional dyspnea, syncope, presyncope, or angina

- Left ventricular ejection fraction (LVEF) <50%

- Clinically significant aortic regurgitation or mitral valve disease

- Prior cardiac surgery

- Positive cardiac stress test

- Medical conditions such as cancer


OTHER SALIENT FEATURES/CHARACTERISTICS:

- Body mass index: 24.5 kg/m2

- Coronary artery disease: 4-5%

- Mean EuroSCORE II: 0.9%

- Cause of aortic stenosis: bicuspid valve: 60%, degenerative: 33%, rheumatic: 6%

- Peak velocity: 5.1 m/sec, mean gradient 64 mm Hg, AVA 0.64 cm2

- Mean LVEF: 65%


PRINCIPAL FINDINGS -

The primary outcome of operative mortality or cardiovascular mortality at 4 years, for early surgery vs. watchful waiting, was 1% vs. 6% (p < 0.05). At 8 years: 1% vs. 26% (p = 0.003).

- Cardiovascular mortality at 4 years: 1% vs. 15% (hazard ratio 0.09, 95% confidence interval 0.01-0.67, p < 0.05)

SECONDARY OUTCOMES FOR EARLY SURGERY VS. WATCHFUL WAITING:

- All-cause mortality at 8 years: 10% vs. 32% (p < 0.05)

- Heart failure hospitalization: 0% vs. 11% (p < 0.05)

- Any secondary endpoint or AVR in watchful waiting group: 62% at 4 years, 92% at 8 years


INTERPRETATION - The results of this trial indicate that early surgery among patients with asymptomatic but very severe aortic stenosis (AVA 0.75 cm2, mean gradient 50 mm Hg, peak velocity 4.5 m/sec) results in improved survival out to 8 years compared with watchful waiting. These are important findings, and will likely change guidelines on this topic. Currently, surgery for asymptomatic aortic stenosis has a Class IIb indication in the American Heart Association/American College of Cardiology valvular heart disease guideline. There are observational data that patients with peak velocity >5 m/sec may particularly benefit, especially if they are low-surgical risk candidates.

A few noteworthy points: Although the surgical risk of these patients was low, there were zero operative deaths, which is likely a reflection of experienced operators/institutions. The generalizability of these findings may thus be harder in a more heterogeneous landscape such as in the United States. Also, it is interesting to note that patients in the watchful waiting arm could go as long as 8 years without crossing over (only two cross-overs to surgery), despite having such severe aortic stenosis. Other studies have suggested this latentperiod (i.e., no symptoms despite severe aortic stenosis) to be about 1-2 years. This cohort had a very high proportion of bicuspid aortic stenosis patients, which may be a partial reason for this. Also, exercise testing was only selectively employed; thus, some patients could have hiddensymptomatic aortic stenosis, which would have been unmasked with a stress test. The EARLY-TAVR trial is looking to enroll a similar asymptomatic population all patients are required to undergo exercise testing for this reason. Finally, these results are not applicable to TAVR; EARLY-TAVR and other studies will help inform this question.